Moreover, emerging clinical data are showing the utility of HDAC inhibition to reverse primary and secondary immune resistance in cutaneous and uveal melanoma as well as non-small cell lung cancer, further increasing excitement about this strategy [21, 22]. Here, HDAC9 is linked to non-small cell lung carcinoma.